J&J Topamax Successor Could Be Ready By 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J identifies RWJ-333369 as potential follow-on to Topamax, and plans to accelerate development ahead of expected topiramate generic entry in 2009. Phase IIb data will be available by end of 2005.